^
EGFR exon 20 insertion
NSCLC
DZD9008
Sensitive: B - Late Trials
PRNewswire - 1 day
EGFR mutation + S100A9 overexpression
Lung Cancer
osimertinib
Resistant: D – Preclinical
Cancer Discov - 3 days
KRAS G12C
NSCLC
sotorasib
Sensitive: A1 - Approval
Amgen Press Release - 1 week
No biomarker
NSCLC
cemiplimab
Sensitive: B - Late Trials
Regeneron Pharmaceuticals Press Release - 1 week
PD-L1 negative
NSCLC
ABBV-181
Sensitive: C3 – Early Trials
J Immunother - 1 week
PD-L1 expression
NSCLC
ABBV-181
Sensitive: C3 – Early Trials
J Immunother - 1 week
IL6 underexpression
NSCLC
ABBV-181
Sensitive: C3 – Early Trials
J Immunother - 1 week
CSF1 underexpression
NSCLC
ABBV-181
Sensitive: C3 – Early Trials
J Immunother - 1 week
CCL23 underexpression
NSCLC
ABBV-181
Sensitive: C3 – Early Trials
J Immunother - 1 week
TMB-H
NSCLC
ABBV-181
Sensitive: C3 – Early Trials
J Immunother - 1 week
KRT7 positive + NKX2-1 positive + ALK overexpression
Lung Cancer
alectinib
Sensitive: C4 – Case Studies
Case Rep Oncol - 1 week
EGFR negative + ALK overexpression
Lung Cancer
alectinib
Sensitive: C4 – Case Studies
Case Rep Oncol - 1 week
PD-L1 overexpression
NSCLC
sintilimab
Sensitive: C3 – Early Trials
NPJ Precis Oncol - 2 weeks
ALK-EML4_V3b + PD-L1 Overexpression
NSCLC
ALK inhibitor
Resistant: C3 – Early Trials
Lung Cancer - 2 weeks
ALK-EML4_V3a + PD-L1 Overexpression
NSCLC
ALK inhibitor
Resistant: C3 – Early Trials
Lung Cancer - 2 weeks
No biomarker
NSCLC
tislelizumab
Sensitive: A1 - Approval
BeiGene Press Release - 3 weeks
PD-L1 expression
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A2 - Guideline
PharmiWeb - 3 weeks
EGFR exon 20 insertion
NSCLC
CLN-081
Sensitive: B - Late Trials
Cullinan Oncology - 3 weeks
No biomarker
NSCLC
pembrolizumab + quaratusugene ozeplasmid
Sensitive: B - Late Trials
Genprex Press Release - 3 weeks
EGFR wild-type + MET overexpression
Lung Non-Squamous Non-Small Cell Cancer
ABBV-399
Sensitive: B - Late Trials
AbbVie Press Release - 3 weeks
EGFR L747P
LUAD
erlotinib
Sensitive: C4 – Case Studies
Anticancer Res - 3 weeks
EGFR exon 19 mutation
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Thorac Cancer - 4 weeks
EGFR exon 19 deletion
NSCLC
Immunotherapy
Sensitive: C3 – Early Trials
Thorac Cancer - 4 weeks
DCTN1-ALK fusion
LUAD
alectinib
Sensitive: C4 – Case Studies
Thorac Cancer - 4 weeks
EGFR exon 19 deletion + EGFR T790M
LUAD
osimertinib
Sensitive: C4 – Case Studies
Thorac Cancer - 4 weeks
PD-L1 expression
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
osimertinib
Sensitive: A1 - Approval
No biomarker
NSCLC
ramucirumab
Sensitive: A1 - Approval
ALK positive
NSCLC
lorlatinib
Sensitive: A1 - Approval
J Thorac Oncol - 2 weeks
EGFR exon 19 deletion
NSCLC
gefitinib
Sensitive: A1 - Approval
EGFR L858R
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
osimertinib
Sensitive: A1 - Approval
Cancer Med - 2 weeks
No biomarker
NSCLC
durvalumab
Sensitive: A1 - Approval
ALK positive
NSCLC
alectinib
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
nivolumab + ipilimumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ALK fusion
NSCLC
brigatinib
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
osimertinib
Sensitive: A1 - Approval
ALK positive
NSCLC
brigatinib
Sensitive: A1 - Approval
ROS1 fusion
NSCLC
entrectinib
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
tepotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab + ipilimumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
dacomitinib
Sensitive: A1 - Approval
Cancer Med - 2 weeks
No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
EGFR T790M
NSCLC
lazertinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
dacomitinib
Sensitive: A1 - Approval
Cancer Med - 2 weeks
MET exon 14 mutation
NSCLC
capmatinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
cemiplimab
Sensitive: A1 - Approval
RET fusion
NSCLC
pralsetinib
Sensitive: A1 - Approval
No biomarker
NSCLC
cisplatin + pemetrexed
Sensitive: A1 - Approval
EGFR mutation
NSCLC
gefitinib
Sensitive: A1 - Approval
Int J Gen Med - 1 week
EGFR L858R
NSCLC
gefitinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
ALK positive
NSCLC
crizotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
pembrolizumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
crizotinib
Sensitive: A1 - Approval
RET fusion
NSCLC
selpercatinib
Sensitive: A1 - Approval
NICE - 2 weeks
EGFR mutation
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
mobocertinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
durvalumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
erlotinib
Sensitive: A1 - Approval
PD-L1 overexpression
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
DP
Sensitive: A1 - Approval
MET exon 14 mutation
NSCLC
savolitinib
Sensitive: A1 - Approval
EGFR mutation
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
dacomitinib
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
Mvasi (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Zirabev (bevacizumab biosimilar)
Sensitive: A1 - Approval
EGFR mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab
Sensitive: A1 - Approval
No biomarker
NSCLC
pemetrexed
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
No biomarker
NSCLC
carboplatin + albumin-bound paclitaxel
Sensitive: A1 - Approval
No biomarker
LUAD
nintedanib
Sensitive: A1 - Approval
EGFR expression
Lung Non-Small Cell Squamous Cancer
necitumumab
Sensitive: A1 - Approval
ALK positive
NSCLC
bevacizumab + atezolizumab
Sensitive: A1 - Approval
BRAF V600E
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
No biomarker
Malignant Pleural Mesothelioma
pemetrexed
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive: A1 - Approval
EGFR exon 20 insertion
NSCLC
amivantamab-vmjw
Sensitive: A1 - Approval
No biomarker
NSCLC
docetaxel
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib
Sensitive: A1 - Approval
ALK positive
NSCLC
ceritinib
Sensitive: A1 - Approval
No biomarker
NSCLC
afatinib
Sensitive: A1 - Approval
EGFR T790M
NSCLC
aumolertinib
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + erlotinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
sintilimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
pembrolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
pembrolizumab
Sensitive: A1 - Approval
EGFR exon 19 deletion
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
No biomarker
NSCLC
erlotinib + Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Aybintio (bevacizumab biosimilar)
Sensitive: A1 - Approval
ALK mutation
NSCLC
pembrolizumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib
Sensitive: A1 - Approval
No biomarker
NSCLC
nivolumab
Sensitive: A1 - Approval
EGFR L858R
NSCLC
erlotinib + ramucirumab
Sensitive: A1 - Approval
ROS1 positive
NSCLC
entrectinib
Sensitive: A1 - Approval
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive: A1 - Approval
ALK positive
NSCLC
atezolizumab
Sensitive: A1 - Approval
EGFR mutation
NSCLC
atezolizumab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
afatinib
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
tislelizumab
Sensitive: A1 - Approval
EGFR mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
ALK mutation
Lung Non-Squamous Non-Small Cell Cancer
nivolumab
Sensitive: A1 - Approval
No biomarker
NSCLC
Bevax (bevacizumab biosimilar)
Sensitive: A1 - Approval
No biomarker
NSCLC
Krabeva (bevacizumab biosimilar)
Sensitive: A1 - Approval
PD-L1 expression
NSCLC
cemiplimab
Sensitive: A1 - Approval
No biomarker
NSCLC
sugemalimab
Sensitive: A1 - Approval
No biomarker
Lung Non-Small Cell Squamous Cancer
sintilimab
Sensitive: A1 - Approval